Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (944)	1/6/1998 1:47:00 AM
From: Cisco	Read Replies (1) \| Respond to of 1894

Sigmund, I believe that NeoPath is hoping to play catch up. Since the AutoPap system is kicking out over 70% of the slides for review, they realize that they need to develop a way to guide the cytotechnologist to the spuspicious cells that the AutoPap finds. Otherwise the system will never be able to justify the cost. Currently, they don't have that technology. Note the comment from their June 24, 1997 release: ®"Initially, the Pathfinder System will be sold as a stand-alone product. Additionally, we will evaluate a potential extension of NeoPath's AutoPap 300 System using the Pathfinder System to guide the cytotechnologist to suspicious cells identified by the AutoPap, thus providing the opportunity to further utilize NeoPath's patented visual intelligence technology which enables the AutoPap to classify slides," said Dr. Alan C. Nelson, president and chief executive officer of NeoPath.¯ I believe that one of the reasons that NeoPath's PMA application for primary screeing was turned down initially was because 70% of all slides were still being referred for review by the cytotechnologist. I only learned recently that the vote on the FDA advisory panel against the application was 9 to 1. It will be interesting to see if they can turn 4 votes. Especially in light of articles like I Can See Clearly Now!, which was published in ASCT Journal of Cytotechnology. This article was clearly poking fun at NeoPath and Neuromedical without naming them. The artcle was reported to this thread earlier: Message 2644654 NPTH is a high risk play at this point with some anaylysts calling for the company not to survive as a company if they lose this round with the FDA. Message 2644880 Cisco